Cannabinoids and breastfeeding
It should seem surprising, as interest grows in cannabinoids as health aids and pharmaceuticals, that Information on cannabinoids in breast milk with maternal cannabis use is still limited.
A team at the Oregon Health Sciences University and the University of Utah has recently undertaken to remedy this, quantifying two cannabinoids in the plasma and breast milk of breastfeeding mothers, and assessing the mothers’ cannabis use patterns overall.*
Breast milk, plasma samples, and survey data were collected from 20 volunteer subjects who used cannabis in the previous 48 hours, at 2 weeks and 2 months postpartum. Median age was 27 years. Median instances of cannabis use in the previous 7 days were 17 (6-29) and 23 (15-45) on visits 1 and 2, respectively. Median THC concentrations were 3.7 ng/ml (plasma) and 27.5 ng/ml (breast milk). Median CBD concentrations were 0.6 ng/ml (plasma) and 1.2 ng/ml (breast milk). The median milk:plasma ratios were 7.0 (THC) and 2.6 (CBD). Median breast milk THC concentration increased from visit 1 to visit 2 by 30.2 ng/ml.
THC and CBD both accumulate in breast milk relative to plasma. Infant exposure to these via breast milk is not known, nor are their effects on infant health.
*Moss MJ, Bushlin I, Kazmierczak S, Koop D, Hendrickson RG, Zuckerman KE, Grigsby TM. Cannabis use and measurement of cannabinoids in plasma and breast milk of breastfeeding mothers. Pediatr Res. 2021 Oct;90(4):861-868. doi: 10.1038/s41390-020-01332-2.
PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis but without residual cannabinoids like THC or any of the impurities or chemicals associated with plant-derived production processes. Our molecular assembly technique, that synthesizes CBD from aromatic terpenes instead of cannabis, assures you the food and pharmaceutical-grade quality that you need for quality-conscious customers. If you are interested in PureForm CBD™ or want to partner on any other of the 140+ known cannabinoids, please contact Damian Peters at310-666-4869, or email info@pureformglobal.com.
The foregoing is a report on trends and developments in the cannabinoid industry. No product described herein is intended to diagnose, treat, cure or prevent any disease or syndrome.